XASXTLX
Market cap5.18bUSD
Dec 20, Last price
24.74AUD
1D
-3.62%
1Q
21.81%
IPO
3,155.26%
Name
Telix Pharmaceuticals Ltd
Chart & Performance
P/E
1,589.15
P/S
16.67
EPS
0.02
Div Yield, %
0.00%
Shrs. gr., 5y
9.88%
Rev. gr., 5y
379.89%
Revenues
497m
+210.23%
Net income
5m
P
CFO
24m
P
Earnings
Feb 20, 2025
Profile
Telix Pharmaceuticals Limited, a radiopharmaceutical company, develops molecularly targeted radiation (MTR) products for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company focuses on developing diagnostic and therapeutic products using MTR. Its lead products include TLX591-CDx for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX66-CDx to treat bone marrow conditioning and rare diseases; TLX250, which is in Phase II clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX250-CDx that is in Phase III clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX591, which is in Phase III clinical trials for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX101 that is in Phase I/II clinical trials and TLX101-CDx for the diagnosis and treatment of glioblastoma (brain cancer); and TLX66, which is in Phase I/IIa clinical trials for the treatment of bone marrow conditioning and rare diseases. The company also develops TLX592, a prostate cancer therapy candidate for targeted alpha therapy; TLX591-Sx, a positron emission tomography (PET) tracer that delivers PET and fluorescent (optical) imaging; and TLX599-CDx, an investigational prostate cancer imaging agent that uses single photon emission computed tomography. It has a strategic license and commercial partnership with China Grand Pharmaceutical and Healthcare Holdings Limited for developing a portfolio of MTR products; scientific and clinical research collaboration with Mauna Kea Technologies; and strategic collaboration agreement with Lightpoint Medical, Ltd. The company was founded in 2015 and is headquartered in North Melbourne, Australia.
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | 496,659 210.23% | 160,096 2,007.64% | 7,596 45.71% | ||||||
Cost of revenue | 450,853 | 282,120 | 112,306 | ||||||
Unusual Expense (Income) | |||||||||
NOPBT | 45,806 | (122,024) | (104,710) | ||||||
NOPBT Margin | 9.22% | ||||||||
Operating Taxes | (2,124) | 5,457 | (18,529) | ||||||
Tax Rate | |||||||||
NOPAT | 47,930 | (127,481) | (86,181) | ||||||
Net income | 5,211 -105.01% | (104,079) 29.27% | (80,510) 79.36% | ||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 6,652 | 165,407 | 3,782 | ||||||
BB yield | -0.20% | -7.32% | -0.17% | ||||||
| Debt | |||||||||
Debt current | 1,559 | 641 | 632 | ||||||
Long-term debt | 24,158 | 9,805 | 3,814 | ||||||
Deferred revenue | 22,522 | 23,056 | |||||||
Other long-term liabilities | 76,097 | 61,807 | 43,226 | ||||||
Net debt | (109,780) | (100,364) | (17,591) | ||||||
| Cash flow | |||||||||
Cash from operating activities | 23,884 | (63,970) | (59,328) | ||||||
CAPEX | (9,679) | (13,861) | (1,339) | ||||||
Cash from investing activities | (25,489) | (16,997) | (2,726) | ||||||
Cash from financing activities | 10,186 | 174,960 | 2,846 | ||||||
FCF | 36,275 | (139,990) | (87,689) | ||||||
| Balance | |||||||||
Cash | 123,237 | 116,329 | 22,037 | ||||||
Long term investments | 12,260 | (5,519) | |||||||
Excess cash | 110,664 | 102,805 | 21,657 | ||||||
Stockholders' equity | 148,911 | 80,007 | 2,158 | ||||||
Invested Capital | 131,789 | 83,111 | 70,305 | ||||||
ROIC | 44.61% | ||||||||
ROCE | 18.89% | ||||||||
| EV | |||||||||
Common stock shares outstanding | 323,710 | 310,644 | 282,206 | ||||||
Price | 10.08 38.65% | 7.27 -6.19% | 7.75 105.03% | ||||||
Market cap | 3,262,997 44.48% | 2,258,382 3.26% | 2,187,096 124.90% | ||||||
EV | 3,153,217 | 2,158,018 | 2,169,506 | ||||||
EBITDA | 52,730 | (116,645) | (99,536) | ||||||
EV/EBITDA | 59.80 | ||||||||
Interest | 13,136 | 406 | 189 | ||||||
Interest/NOPBT | 28.68% | ||||||||